# Tafluprost

## Taflotan-S 0.0015%，0.3mL ophthalmic solution

##### 

| TAH Drug Code      | [ETAFS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ETAFS)                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Instill 1 drop in the affected eye(s) once daily in the evening.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypersensitivity to Tafluprost.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | >10%: Ocular: Conjunctival hyperemia (4% to 20%) 1% to 10%: Central nervous system: Headache (6%) Genitourinary: Urinary tract infection (2%) Ocular: Stinging/irritation (7%), conjunctivitis (5%), cataract (3%), dry eye (3%), ocular pain (3%), eyelash darkening (2%), eyelash growth (2%), vision blurred (2%) Respiratory: Common cold (4%), cough (3%) Postmarketing and/or case reports (Limited to important or life-threatening): Dyspnea, exacerbation of asthma; macular edema (reported with prostaglandin analog use) |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

